Final Supreme Court Ruling against Korea United in Drug Pricing Lawsuit... Damages of 24.1B KRW Confirmed, 5.3% of Equity


  • The Supreme Court dismissed the appeal by the National Health Insurance Service, making final the lower court ruling that Korea United must pay damages in the drug pricing lawsuit.
  • Korea United is now liable for 24.1 billion KRW (5.3% of equity), based on individual financial statements at end-2025 with equity of 454.6 billion KRW, a manageable amount.
  • Although the ruling results in immediate cash outflow, it removes legal uncertainty and closes the long-standing litigation.

KOSPI Filing Information


  • Filing: Judgment/Decision on Lawsuits, etc. (Claims of a Certain Amount or More)
  • Company: KOREA UNITED PHARM (033270)
  • Submission: KOREA UNITED PHARM INC
  • Receipt: 05-29-2026
  • Under KRX KOSPI Market Division